Abstract
After the metabolic syndrome and its components, thyroid disorders represent the most common endocrine disorders, with increasing prevalence in the last two decades. Thyroid dysfunctions are distinguished by hyperthyroidism, hypothyroidism, or inflammation (thyroiditis) of the thyroid gland, in addition to the presence of thyroid nodules that can be benign or malignant. Thyroid cancer is typically detected via an ultrasound (US)-guided fine-needle aspiration biopsy (FNAB) and cytological examination of the specimen. This approach has significant limitations due to the small sample size and inability to characterize follicular lesions adequately. Due to the rapid advancement of high-throughput molecular biology techniques, it is now possible to identify new biomarkers for thyroid neoplasms that can supplement traditional imaging modalities in postoperative surveillance and aid in the preoperative cytology examination of indeterminate or follicular lesions. Here, we review current knowledge regarding biomarkers that have been reliable in detecting thyroid neoplasms, making them valuable tools for assessing the efficacy of surgical procedures or adjunctive treatment after surgery. We are particularly interested in providing an up-to-date and systematic review of emerging biomarkers, such as mRNA and non-coding RNAs, that can potentially detect thyroid neoplasms in clinical settings. We discuss evidence for miRNA, lncRNA and circRNA dysregulation in several thyroid neoplasms and assess their potential for use as diagnostic and prognostic biomarkers.
Introduction: The Diagnostic "Gray Zone"
Thyroid disorders are among the most prevalent endocrine conditions globally. While ultrasound-guided fine-needle aspiration biopsy (FNAB) remains the clinical "gold standard" for diagnosing thyroid cancer, it faces a significant challenge: the diagnostic "gray zone." Approximately 15% to 25% of FNAB cases result in "indeterminate" or "follicular" findings, where cytology alone cannot confirm malignancy. This often leads to unnecessary diagnostic surgeries or, conversely, delayed treatment for aggressive cancers.
To address these limitations, researchers are turning to high-throughput molecular biology to identify biomarkers that can refine risk stratification and improve postoperative monitoring.
Emerging Molecular Tools: mRNA and Non-Coding RNAs
The rapid advancement of molecular techniques, such as Next-Generation Sequencing (NGS) and quantitative RT-PCR, has enabled the identification of specific genetic signatures associated with thyroid neoplasms.
The Role of Non-Coding RNAs
A major focus of current research is the role of non-coding RNAs (ncRNAs), which include microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA). These molecules act as critical regulators of gene expression:
- miRNAs: Specific miRNAs like miR-146b have emerged as powerful markers for Papillary Thyroid Carcinoma (PTC), correlating with tumor invasion. For Medullary Thyroid Carcinoma (MTC), miR-375 has demonstrated a remarkable 92.6% sensitivity and 97.6% specificity in distinguishing patients from healthy controls.
- circRNAs: These molecules can act as "miRNA sponges," soaking up microRNAs that would otherwise silence tumor-suppressor genes. Understanding these dysregulation signatures allows for high-precision diagnosis.
Circulating mRNA and Commercial Panels
Detecting mRNA for proteins like Thyroglobulin (Tg) or the TSH receptor (TSHR) in the blood can indicate the presence of circulating thyroid cells, potentially signaling metastatic potential. Furthermore, commercial molecular panels like ThyGeNEXT and ThyraMIR are already being utilized in clinical settings to categorize indeterminate nodules into low, moderate, or high-risk groups, significantly reducing the rate of unnecessary diagnostic lobectomies.
Key Results and Clinical Benchmarks
The review highlights several quantitative successes in the field:
- Differential Diagnosis: Serum diiodotyrosine (DIT) levels can distinguish destructive thyroiditis from Graves’ disease with 84.6% sensitivity, offering a chemical alternative to traditional uptake scans.
- Mutation Analysis: The BRAF V600E mutation is present in 30% to 77% of PTC cases. While its presence is a strong indicator of malignancy, its utility as a prognostic marker for tumor aggressiveness remains a subject of ongoing debate.
Limitations and Future Directions
Transitioning these biomarkers from research to routine clinical practice requires overcoming several hurdles. Many current studies rely on small, single-center cohorts, and there is a pressing need for large-scale, multicenter validation. Additionally, the lack of standardized protocols for sample handling and RNA isolation often leads to conflicting results across different laboratories.
The authors advocate for a "personalized medicine" approach, where the integration of multi-marker panels and NGS into routine workflows allows a patient's specific molecular profile to dictate their surgical and follow-up plan, ultimately improving clinical outcomes and patient quality of life.
Summary updated